Stock Events

Stock Events

Adc Therapeutics SA 

$1.3250
54
+$0.00+0.38% 15:24 Today

Statistics

Day High
1.33
Day Low
1.305
52W High
4.98
52W Low
0.78
Volume
237,421
Avg. Volume
1,878,361
Mkt Cap
169.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.5
-0.37
-0.24
-0.11
Expected EPS
-0.212
Actual EPS
N/A

Financials

-175.31%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
81.36MRevenue
-142.62MNet Income

Analyst Ratings

3.50Average Price Target
The highest estimate is 5.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADCT. It's not an investment recommendation.
Apple
9
AAPL
Microsoft
9
MSFT
Amazon
9
AMZN
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Macrogenics
MGNX
Mkt Cap263.08M
MacroGenics provides innovative antibody-based therapies, including ADCs, targeting cancer, making it a direct competitor.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics works on allogeneic CAR T therapies for cancer, competing in the broader oncology market against ADCT.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space, particularly in therapies that overlap with ADCT's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a range of cancer treatments, including ADCs, positioning it as a competitor in the oncology therapeutic market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse oncology portfolio, including ADCs and other cancer therapies, competing with ADCT.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on innovative treatments for cancer, including bi-specific antibodies, places it in competition with ADCT.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its strong presence in oncology and investments in ADCs, is a significant competitor in the cancer treatment market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer offers a broad range of oncology treatments, including ADCs, making it a competitor in the same therapeutic area as ADCT.

About

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Show more...
CEO
Ameet Mallik
Employees
193
Country
Switzerland
ISIN
CH0499880968

Listings

BOATS
BOATS
ADCT.BOATS
XNYS
US
ADCT

0 Comments

Share your thoughts

FAQ

What is Adc Therapeutics SA stock price today?▼
The current price of ADCT is $1.33 USD — it has increased by +0.38% in the past 24 hours. Watch Adc Therapeutics SA stock price performance more closely on the chart.
What is Adc Therapeutics SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Adc Therapeutics SA stocks are traded under the ticker ADCT.
Is Adc Therapeutics SA stock price growing?▼
ADCT stock has risen by +14.91% compared to the previous week, the month change is a +19.09% rise, over the last year Adc Therapeutics SA has showed a -61.47% decrease.
What is Adc Therapeutics SA market cap?▼
Today Adc Therapeutics SA has the market capitalization of 169.16M
When is the next Adc Therapeutics SA earnings date?▼
Adc Therapeutics SA is going to release the next earnings report on November 10, 2026.
What were Adc Therapeutics SA earnings last quarter?▼
ADCT earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.22 USD resulting in a +49.07% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adc Therapeutics SA revenue for the last year?▼
Adc Therapeutics SA revenue for the last year amounts to 81.36M USD.
What is Adc Therapeutics SA net income for the last year?▼
ADCT net income for the last year is -142.62M USD.
How many employees does Adc Therapeutics SA have?▼
As of September 04, 2026, the company has 193 employees.
In which sector is Adc Therapeutics SA located?▼
Adc Therapeutics SA operates in the Health & Wellness sector.
When did Adc Therapeutics SA complete a stock split?▼
The last stock split for Adc Therapeutics SA was on May 10, 2005 with a ratio of 1:7.
Where is Adc Therapeutics SA headquartered?▼
Adc Therapeutics SA is headquartered in EPALINGES, Switzerland.